A share price of Terns Pharmaceuticals Inc [TERN] is currently trading at $7.53, down -7.95%. An important factor to consider is whether the stock is rising or falling in short-term value. The TERN shares have gain 4.15% over the last week, with a monthly amount glided 19.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Terns Pharmaceuticals Inc [NASDAQ: TERN] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $15. On February 28, 2025, William Blair initiated with a Mkt Perform rating. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $82 on October 31, 2024. Mizuho initiated its recommendation with a Buy and recommended $16 as its price target on June 22, 2023. Jefferies started tracking with a Buy rating for this stock on June 07, 2023, and assigned it a price target of $18. In a note dated May 31, 2023, ROTH MKM initiated a Buy rating and provided a target price of $23 on this stock.
Terns Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.87 and $10.70. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $7.53 at the most recent close of the market. An investor can expect a potential return of 99.2% based on the average TERN price forecast.
Analyzing the TERN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.27 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Terns Pharmaceuticals Inc [NASDAQ:TERN] is 24.70. On the other hand, the Quick Ratio is 24.70, and the Cash Ratio is 11.3.
Transactions by insiders
Recent insider trading involved Kuriakose Emil, Chief Medical Officer, that happened on Jul 01 ’25 when 853.0 shares were sold. Chief Financial Officer, Gengos Andrew completed a deal on Jun 27 ’25 to buy 10000.0 shares. Meanwhile, Chief Executive Officer Burroughs Amy L. bought 23314.0 shares on Jun 25 ’25.
